Further investigation of the epitope recognized by the new monoclonal antibody 2C9

International Journal of Urology

Volumn 10, Issue 8, 2003, Pages 439-444

  Kato, Keitaro ^a   Yoshikawa, Kazuhiro ^a   Taki, Tomohiro ^a   Shitara, Kenya ^b   Nakamura, Kazuyasu ^b   Hirota, Maiko ^b   Hanai, Nobuo ^b   Nakamura, Kogenta ^a   Kokubo, Hiroto ^a   Mitsui, Kenji ^a   Yamada, Yoshiaki ^a   Honda, Nobuaki ^a   Ueda, Ryuzo ^c   Saga, Shinsuke ^a   Fukatsu, Hidetoshi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

2C9; Monoclonal antibody; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

ANTIBODY; COMPLEMENTARY DNA; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2C9; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ARTICLE; CLONING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; BLOTTING, NORTHERN; CELL LINE, TUMOR; CLONE CELLS; DNA, COMPLEMENTARY; EPITOPE MAPPING; EPITOPES; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 10744219584     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2003.00655.x     Document Type: Article

References (19)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999: challenges in minority populations. CA Cancer J. Clin. 1999; 49: 8-31.
2. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 2000; 85: 60-7.
3. Killian CS, Vargas FP, Slack NH, Murphy GP, Chu TM. Prostate-specific acid phosphatase versus acid phosphatase in monitoring patients with prostate cancer. Ann. NY Acad. Sci. 1982; 390: 122-32.
4. Cupp MR, Oesterling JE. Prostate-specific antigen, digital rectal examination, and transrectal ultrasonography: their roles in diagnosing early prostate cancer. Mayo Clin. Proc. 1993; 68: 297-306.
5. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987; 7: 927-35.
6. Murphy GP, Holmes EH, Boynton AL et al. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate 1995; 26: 164-8.
7. Israeli RS, Powell CT, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994; 54: 1807-11.
8. Rinker-Schaeffer CW, Hawkins AL, Su SL et al. Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics 1995; 30: 105-8.
9. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. USA 1996; 93: 749-53.
10. Babaian RJ, Sayer J, Podoloff DA, Steelhammer LC, Bhadkamkar VA, Gulfo JV. Radioimmunoscintigraphy of pelvic lymph nodes with 11 lindium-labeled monoclonal antibody CYT-356. J. Urol. 1994; 152: 1952-5.
11. Taki T. Production of a monoclonal antibody specifically reacted to prostate tissues. J. Aichi Med. Univ. Assoc. 1995; 23: 609-19.
12. Sasaki K, Kurata K, Kojima N et al. Expression cloning of a GM3-specific alpha-2,8-sialyltransferase (GD3 synthase). J. Biol. Chem. 1994; 269: 15950-6.
13. Hirt B. Selective extraction of polyma DNA from infected mouse cell cultures. J. Mol. Biol. 1967; 26: 365-9.
14. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294-9.
15. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res. 1998; 58: 4787-9.
16. Liu H, Moy P, Kim S et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997; 57: 3629-34.
17. Gong MC, Chang SS, Sadelain M, Bander NH, Heston WD. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev. 1999; 18: 483-90.
18. Wang S, Diamond DL, Hass GM, Sokoloff R, Vessella RL. Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip; array, surface-enhanced laser desorption/ionization (SELDI) technology. Int. J. Cancer 2001; 92: 871-6.
19. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer 1995; 62: 552-8.